GLP toxicology study for SBT6290 (Nectin4-TLR8 ImmunoTAC) is nearing completion, with IND filing on track for the fourth quarter of 2021.
#SILVERBACK THERAPEUTICS TRIAL#
Under the terms of the agreement, Silverback will expand the ongoing Phase 1/1b trial to evaluate the combination of SBT6050 and Libtayo ® in tumor-specific dose expansion cohorts, initially in HER2-expressing non-small cell lung and gastric cancers.
Session Date and Time: The ePoster will be released virtually on Thursday, September 16 th at 8:30 AM Central European Summer Time / 2:30 AM Eastern Standard TimeĪnnounced a clinical supply agreement with Regeneron to evaluate SBT6050 in combination with Libtayo ® (cemiplimab), a PD-1 inhibitor.
Title: 'Interim results of a Phase 1/1b study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors ' Klempner, S., et al. Details of the upcoming ESMO poster presentation are as follows:
#SILVERBACK THERAPEUTICS UPDATE#
The presentation will provide an update on the monotherapy dose-escalation arm (Part 1) and the pembrolizumab combination dose-escalation arm (Part 3) of the SBT6050-101 Phase 1/1b study. SBT6050 (HER2-TL8 ImmunoTAC) clinical abstract accepted for poster presentation at the European Society for Medical Oncology ('ESMO') 2021 Annual Meeting. 'We are deeply appreciative of the patients, their families, and our clinical investigators who continue to contribute to the SBT6050-101 clinical trial, and we look forward to providing the first update of the clinical data at the ESMO conference in September.' 'The second quarter was notable for the significant progress we made across our entire pipeline of tissue-targeted therapies, with SBT6050, our HER2-TLR8 ImmunoTAC leading the way with continued robust enrollment in our Phase 1/1b study,' said Laura Shawver, Ph.D., chief executive officer of Silverback. (Nasdaq: SBTX) ('Silverback'), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today reported financial results for the second quarter ended Jand provided a business update. SEATTLE - AugSilverback Therapeutics, Inc. The Kirkland team was led by corporate partners Dan Vaczy and Christian Atwood, tax partner Vincent Thorn, and investment funds partner Amala Ejikeme and associate Anna Alexandrou.Silverback Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update Upon stockholder approval, the combined company is expected to operate under the name ARS Pharmaceuticals and trade on the Nasdaq Capital Market under the ticker symbol “SPRY.” The merger is currently expected to close in the fourth quarter of 2022. The combined company is expected to have approximately $265 million in cash, cash equivalents and marketable securities at closing.
The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. (ARS), under which ARS will merge with Silverback in an all-stock transaction. (Silverback), and ARS Pharmaceuticals, Inc. Kirkland & Ellis advised Nextech, a global, cancer therapeutics-focused venture capital firm, in connection with a definitive agreement between its portfolio company, Silverback Therapeutics, Inc.
0 kommentar(er)
